对46名接受奥昔芬治疗12周的外阴阴道萎缩女性进行回顾性分析：膀胱过度活动症症状改善。
Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
作者信息
Schiavi Michele Carlo, Zullo Marzio Angelo, Faiano Pierangelo, D'Oria Ottavia, Prata Giovanni, Colagiovanni Vanessa, Giannini Andrea, Di Tucci Chiara, Perniola Giorgia, Di Donato Violante, Monti Marco, Muzii Ludovico, Benedetti Panici Pierluigi
机构信息
a Department of Gynecological and Obstetric Sciences, and Urological Sciences , University of Rome "Sapienza", Umberto I Hospital , Rome , Italy and.
b Department of Surgery-Week Surgery, Campus Biomedico , University of Rome , Rome , Italy.
出版信息
Gynecol Endocrinol. 2017 Dec;33(12):942-945. doi: 10.1080/09513590.2017.1323859. Epub 2017 May 11.
AIMS
The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA).
METHODS
Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60 mg for 12 weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12 weeks. Patients completed the OAB-Q SF and UDI-6.
RESULTS
After 12-weeks, the number of patients with detrusor overactivity decreased from 39% to 13% (p = 0.04). The reduction in the mean number in 24 h of voids (9.57 ± 2.12 vs. 6.63 ± 1.22, p < 0.0001), urgent micturition episodes/24 h (5.63 ± 1.46 vs. 1.44 ± 1.31, p < 0.0001), nocturia episodes (3.17 ± 0.85 vs. 1.11 ± 1.18, p < 0.0001), urinary incontinence episodes/24 h (0.85 ± 0.96 vs. 0.33 ± 0.64, p = 0.003) was observed. The UDI-6, OAB-Q symptoms, OAB-Q (HRQL) scores were 8.95 ± 0.91 vs. 5.56 ± 1.40, 62.60 ± 14.70 vs. 20.08 ± 10.83 and 18.71 ± 7.41 vs. 79.45 ± 14.47 (p < 0.001) before and after 12 weeks.
CONCLUSION
Ospemifene is an effective potential therapy for postmenopausal women with VVA improving OAB symptoms and quality of life.
目的
本研究旨在评估奥昔芬改善受外阴阴道萎缩（VVA）影响的绝经后女性膀胱过度活动症（OAB）症状的有效性和安全性。
方法
46例患有VVA合并OAB综合征的绝经后患者纳入本研究。所有患者接受60mg奥昔芬治疗12周。在基线和12周时进行临床检查、3天排尿日记、尿动力学检测、子宫内膜及膀胱壁厚度（BWT）超声测量以及阴道健康指数（VHI）评估。患者完成OAB-Q SF和UDI-6问卷。
结果
12周后，逼尿肌过度活动患者数量从39%降至13%（p = 0.04）。24小时平均排尿次数减少（9.57±2.12对6.63±1.22，p < 0.0001），尿急发作次数/24小时（5.63±1.46对1.44±1.31，p < 0.0001），夜尿次数（3.17±0.85对1.11±1.18，p < 0.0001），尿失禁发作次数/24小时（0.85±0.96对0.33±0.64，p = 0.003）。12周前后UDI-6、OAB-Q症状、OAB-Q（HRQL）评分分别为8.95±0.91对5.56±1.40、62.60±14.70对20.08±10.83、18.71±7.41对79.45±14.47（p < 0.001）。
结论
奥昔芬是一种有效的潜在治疗方法，可改善患有VVA的绝经后女性的OAB症状和生活质量。
Zotero 插件